Overview

A Phase 2 Study of the Effects of Sapropterin Dihydrochloride on Symptomatic Peripheral Arterial Disease

Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether sapropterin dihydrochloride is safe and effective in the treatment of intermittent claudication (IC) caused by peripheral arterial disease (PAD).
Phase:
Phase 2
Details
Lead Sponsor:
BioMarin Pharmaceutical
Treatments:
Ascorbic Acid
Verapamil
Vitamins